Table 1.

Cardiovascular risk factors, clinical data and medication (n (%) or median [IQR]) (n = 284)

metformin	Metformin n = 119	No Metformin n = 165	p value
Risk factors
Age ≥ 65 years	28 (23.5%)	46 (27.9%)	0.410
Women	26 (21.8%)	47 (28.5%)	0.207
Diabetes duration≥5 years	80 (67.2%)	99 (60.0%)	0.430
Hypertension	74 (62.2%)	114 (69.1%)	0.225
Hyperlipidemia	53 (44.5%)	61 (37.0%)	0.199
Current smoking	80 (67.2%)	99 (60.0%)	0.213
Stroke	8 (6.7%)	14 (8.5%)	0.586
Prior myocardial infarction	16 (13.4%)	12 (7.3%)	0.085
PAD	3 (2.5%)	4 (2.4%)	0.959
Medical therapy initiated during hospitalization
Other oral antihyperglycemic agent.	60 (50.4%)	73 (44.2%)	0.303
ACEI or ARB	51 (42.9%)	68 (41.2%)	0.782
Mineralocorticoid receptor antagonist	4 (3.4%)	7 (4.2%)	0.946
Calcium-channel blocker	6 (5.0%)	5 (3.0%)	0.579
Beta-blocker	95 (79.8%)	99 (60%)	< 0.05
Metformin dosage			0.230
> 0 g to ≤0.5 g	1 (0.8%)	7 (4.2%)
> 0.5 g to ≤1 g	32 (26.9%)	36 (21.8%)
> 1 g to ≤1.5 g	85 (71.4%)	118 (71.5%)
> 1.5 g	1 (0.8%)	4 (2.4%)
Clinical data
LVEF≤40%	7 (5.9%)	11 (6.7%)	0.789
Time to PCI (hour)	4 (6–16)	6 (4–9)	0.139
Single--vessel disease	31 (26.1%)	45 (27.3%)	0.818
Infarct-related artery
Left main	0 (0%)	1 (0.6%)	1.000
Left anterior descending coronary artery	56 (47.1%)	83 (50.3%)	0.589
Left circumflex coronary artery	17 (14.3%)	20 (12.1%)	0.593
Right coronary artery	47 (39.5%)	60 (36.4%)	0.591
Contrast media volume (ml)	120 (120–200)	150 (110–200)	0.884

PAD peripheral arterial disease, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention